Answers are grounded in this paper and cite their sources.
Rheumatoid Arthritis (RA) is the most common form of chronic inflammatory arthritis that affects about 18 million people worldwide.Genetic and environmental risk factors initiate the onset of RA, while gene-environment interactions involving epigenetic mechanisms (such as aberrant DNA methylations and dysregulated histone modifications) trigger the upregulation of pro-inflammatory genes or the downregulation of anti-inflammatory counterparts.Given the presence of autoantibodies against rheumatoid factor and citrullinated proteins, it is considered an autoimmune disease involving accumulation and activation of several leukocyte subpopulations including T-cells releasing T-cell derived cytokines, B-cells with subsequent autoantibody responses and macrophage-like and fibroblast-like cells which produce large amounts of pro-inflammatory cytokines.Disease management follows a stepwise approach using disease-modifying antirheumatic drugs to achieve sustained remission or at least low disease activity.Nevertheless, a significant proportion of patients show a refractory disease necessitating further research.Novel biologics are in development mainly targeting pathogenic B-and T-cell responses, inflammatory cytokines and co-stimulatory pathways or protein citrullination.Novel small molecules acting on certain melanocortin receptors may rebalance the immune system.Innovative cell therapies are emerging, including products based on T-cells with chimeric antigen receptors (CARs) that target B-cell proteins and have already demonstrated drug-free remission in individual case studies.
No takes yet. Share an insight, caveat, or question.
Claudia L. Werner (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: